Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.

Original reporting
Published Sep 18, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 2:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX) — source image
Decision brief

The 30-second read

$ENTXBullishMed
01

Why it matters

Analyst initiation and a sizable private placement provide fresh catalysts that could move the stock toward the new $9 target.

02

Market read

New coverage and financing create a short‑term bullish catalyst for ENTX, while the Phase 3 trial timeline sets longer‑term risk/reward.

03

What to watch

Potential competition from other oral anabolic agents and reimbursement uncertainties could limit upside.

Relevance 7/10Novelty 7/10Timing: post‑market Sep 18 2026

Background

Entera Bio (NASDAQ:ENTX) is developing an oral PTH peptide for osteoporosis, having completed Phase 2 and now preparing for Phase 3.

Company-level read

Ticker impact

$ENTXBullishHigh confidence
Context

Leerink Partners initiates coverage with an Outperform rating and a $9 price target, and the company completed a $275 million private placement to fund its Phase 3 trial.

Expected impact

Potential price appreciation toward the $9 target over the next weeks to months.

Evidence & confidence

The combination of a fresh buy‑side rating, a higher price target, and a large cash infusion reduces financing risk and validates the Phase 3 program.

Market effects

Strengthens the oral‑peptide biotech niche and may boost peer valuations in osteoporosis therapeutics.

Highlights continued capital availability for U.S. biotech firms despite broader market volatility.

Shows investor appetite for innovative drug delivery platforms worldwide.

Counterpoint

The Phase 3 outcome remains uncertain; the $9 target may be overly optimistic given execution risk.

Key entities

  • Leerink Partners

    Initiated coverage with Outperform rating and $9 price target.

  • BVF Partners

    Lead investor in the $275 million private placement.

Related articles

$ENTXMedAI 8/10

A planned osteoporosis pill trial is expected to enroll about 900 women. Entera expects its first site to open in late 2026.

Entera Bio (ENTX) plans to initiate a Phase 3 trial for its osteoporosis drug EB613 in late 2026, with 900 women expected to enroll. The company presented Phase 2 data at ASBMR 2026, showing potential benefits for patients with low bone mineral density. Entera also announced key leadership appointments and financial results for Q3 2026.

$ENTXMedAI 8/10

Entera Bio to present Phase 3 trial design for oral osteoporosis drug

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

$ENTXMedAI 8/10

Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million

Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.